Compare UK prices. 40+ products · 15 retailers scored
PeptideClear UK

Regulatory hub · UK status

BPC-157: UK regulatory status

Also known as: Body Protection Compound 157, Pentadecapeptide BPC-157

Last reviewed . Editorial commentary, not legal advice.

MHRA: No UK marketing authorisation Prohibited (WADA S0, non-approved substances)
AI-friendly summary · BPC-157

BPC-157 is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It holds no UK marketing authorisation as a medicine. WADA lists it under S0 of the Prohibited List for in-competition and out-of-competition use.

Misuse of Drugs Act 1971

BPC-157 does not appear on any schedule of the Misuse of Drugs Act 1971 or its associated regulations. Possession in the UK is not criminalised under controlled-drugs law.

Psychoactive Substances Act 2016

BPC-157 is not covered by the Psychoactive Substances Act 2016. The Act targets substances that affect the central nervous system; BPC-157 is not characterised as psychoactive.

MHRA and medicines classification

BPC-157 holds no UK marketing authorisation as a medicine. UK research peptide retailers list it under "research use only, not for human or animal consumption" framing. The moment a seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.

See: MHRA medicines classification (POM, P, GSL).

WADA Prohibited List position

BPC-157 appears under WADA S0 (non-approved substances) and is prohibited at all times for tested athletes under UK Anti-Doping (UKAD) jurisdiction.

See: WADA Prohibited List and peptides.

ASA advertising framing

UK sellers cannot make therapeutic claims for BPC-157. ASA has previously upheld rulings against research peptide retailers who described BPC-157 as a tissue-healing or recovery product in paid advertising.

See: ASA rules on weight-loss advertising.

Primary sources

When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.

Frequently asked questions

Is BPC-157 legal in the UK?
BPC-157 is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It holds no UK marketing authorisation as a medicine. WADA lists it under S0 of the Prohibited List for in-competition and out-of-competition use.
What is the MHRA position on BPC-157?
BPC-157 holds no UK marketing authorisation as a medicine. UK research peptide retailers list it under "research use only, not for human or animal consumption" framing. The moment a seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.
Is BPC-157 on the WADA Prohibited List?
BPC-157 appears under WADA S0 (non-approved substances) and is prohibited at all times for tested athletes under UK Anti-Doping (UKAD) jurisdiction.
What can UK sellers say about BPC-157 in adverts?
UK sellers cannot make therapeutic claims for BPC-157. ASA has previously upheld rulings against research peptide retailers who described BPC-157 as a tissue-healing or recovery product in paid advertising.

Related: BPC-157 editorial entry · UK regulatory hub.

Related on PeptideClear

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-22T12:00:00.000Z